Aurobindo Files First Biosimilar In Europe With Pegfilgrastim
Indian Giant’s CuraTeQ Subsidiary Files BP14 Neulasta Rival With EMA
Aurobindo has submitted its first biosimilar application to the EMA, with the Indian company’s CuraTeQ subsidiary filing its BP14 pegfilgrastim rival to Neulasta.
You may also be interested in...
While its COVID-19 vaccine, partnered with US-based Vaxxinity, is set to move to Phase III trials, Aurobindo has acquired an animal health company as well as several ANDAs and OTC assets. The acquisition and a deceleration in US sales caught analysts by surprise.
Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market.
Aurobindo expects the first data readouts from the Phase II/III clinical trials of its partnered COVID-19 vaccine by July. While making progress in biosimilars development, the Indian company also plans to invest substantially in new API capacity.